The Glucagon-Like Peptide-1 Receptor—or Not?
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1)-based diabetes therapy is increasingly used in the treatment of type 2 diabetes. Two GLP-1 analogs, liraglutide and exenatide, have been approved for clinical use and act as agonists of the GLP-1 receptor (GLP-1R), a member of the glucagon receptor family of G protein-coupled receptors (GPCRs) (1). Also, the clinical effect of Di-Peptidyl Peptidase-4 (DPP-4) inhibitors is at least partially resulting from an increased level of active GLP-1 (2). The unambiguous identification of GLP-1R-expressing cells in humans and animal species constitutes critically important knowledge for fully understanding the pharmacological effects of GLP-1R agonists, both those associated with the documented clinical benefits as well as any potential undesired effects of treatment. The GLP-1R was cloned in 1992 (3). Preceding that, the receptor was identified in numerous cell types and organs, most obviously the pancreatic β-cell but also in rat lung and brain by studies using either ligand binding or functional assays (4, 5). After the receptor was cloned, RT-PCR and in situ hybridization were used to report tissue distribution, and the receptor was located in the intestine, stomach, kidney, lungs, heart, and brain (6, 7). Later studies have used Western blotting and immunohistochemistry to identify the exact cellular localization of the receptor. Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9). Human GLP-1R expression has been mapped by in situ ligand binding across a wide range of both normal and tumor tissues (10). In this issue of Endocrinology, Panjwani et al. (11) reports new knowledge about the mechanism of action of GLP-1 analogs in atherosclerosis and hepatic steatosis and challenges some GLP-1R expression data in macrophages and hepatocytes that have previously been published. When Panjwani et al. (11) could not identify GLP-1R mRNA on macrophages or isolated hepatocytes despite previous reports of such localization, they did a careful Western blotting characterization of three commercially available polyclonal antibodies (PAbs) against the GLP-1R that are commonly used for Western blotting. They used mouse wild-type lung tissue that has a very high expression of GLP-1R as a positive control and lung tissue from GLP-1R−/− mice as a negative control. They also employed a very thorough procedure with immunoprecipitation in an attempt to increase the sensitivity of the analysis but found no GLP-1R-specific expression. The authors conclude that multiple commercially available GLP-1R antibodies do not detect authentic GLP-1R protein, even using optimally enhanced methods. This technical difficulty at first glance seems to have little bearing on aspects of GLP-1 biology unrelated to the scope of the article; however, on further consideration, it brings into focus a potentially serious problem with the validity of any GLP-1R expression data generated through the use of antibodies. Adding to the complexity, for some GLP-1R-containing organs, markedly different GLP-1R expression patterns have been reported between human and rodent species (10, 12). Rodent thyroid C-cells express much higher levels of GLP-1R than primates (10, 12), and there may be an important species difference, where the GLP-1R in the rodent thyroid is important for the high bone turnover in those species but less important in humans (13, 14). In the lung, the number of GLP-1R-expressing cells and the receptor density is much lower in humans than in rodent species (10), but the role and importance of lung GLP-1R is relatively unexplored. Three different histological techniques are available for mapping the identity of cells expressing a receptor like the GLP-1R. First, in situ hybridization is the method of choice for detecting mRNA in tissues; however, for a low-abundance target like the GLP-1R, only methods depending on the use of radioactively labeled probes will provide the required sensitivity, and unfortunately, the final autoradiography step severely limits the resolution of the output signal. A similar problem exists for in situ ligand binding (ISLB) with radioactively labeled ligand, although this method has been highly useful for detecting a functional GLP-1R in cell types that can be identified despite the limited resolution (12, 15). The third method, and the one most often employed to map GLP-1R localization by researchers in the field, is immunohistochemistry (IHC) with anti-GLP-1R antibodies. IHC offers the best resolution and allows unambiguous cell identification; however, for GPCRs, it is notoriously difficult, and a high focus on validation of antibodies and protocols is imperative. Further adding to the difficulty of generating reliable GPCR protein expression data, the normal physiological cell density of many GPCRs can be very low. In one issue of the journal Naunyn-Schmiedeberg’s Archives
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [39]
In the citing paper
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [11]
In the citing paper
“However, these studies were later refuted, as incompletely validated GLP-1 receptor antisera were used (81).”
From Safety of Semaglutide (2021) · cites this paper as [81]
Citations
Cites
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9).”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Self-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 1×
“the intestine, stomach, kidney, lungs, heart, and brain (6, 7).”
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“Adding to the complexity, for some GLP-1R-containing organs, markedly different GLP-1R expression patterns have been reported between human and rodent species (10, 12).”
BackgroundInfluentialGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“A similar problem exists for in situ ligand binding (ISLB) with radioactively labeled ligand, although this method has been highly useful for detecting a functional GLP-1R in cell types that can be identified despite the limited resolution (12, 15).”
MethodCampos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 2×
“(11) reports new knowledge about the mechanism of action of GLP-1 analogs in atherosclerosis and hepatic steatosis and challenges some GLP-1R expression data in”
BackgroundThe Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
How reliable are G-protein-coupled receptor antibodies?
Michel, M. C., Wieland, T., & Tsujimoto, G. (2009) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-009-0395-y · Cited by 306
Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas
Tornehave, D., Kristensen, P., Rømer, J., Knudsen, L. B., & Heller, R. S. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.951319 · Cited by 248 · cited 1×
“Due to discontinuation of supply, we were not able to include the PAb LS-A1206, also recommended for IHC on paraffin-embedded human material, and used in other studies (25, 26).”
MethodSelf-citationGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Brubaker, P. L., & Drucker, D. J. (2002) · Receptors and Channels · doi:10.1080/10606820213687 · Cited by 198 · cited 3×
“the ability of antibodies to react with human GLP-1R-transfected cells and not with nontransfected Endocrinology, January 2013, 154(1):4–8 endo.”
BackgroundInfluentialHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“Rodent thyroid C-cells express much higher levels of GLP-1R than primates (10, 12), and there may be an important species difference, where the GLP-1R in the rodent thyroid is important for the high bone turnover in those species but less important in humans (13, 14).”
BackgroundTen commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific
Jensen, B. C., Swigart, P. M., & Simpson, P. C. (2009) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-008-0368-6 · Cited by 176
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
Pradidarcheep, W., Stallen, J., Labruyère, W. T., Dabhoiwala, N. F., Michel, M. C., & Lamers, W. H. (2009) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-009-0393-0 · Cited by 152
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
Schlatter, P., Beglinger, C., Drewe, J., & Gutmann, H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.016 · Cited by 149 · cited 1×
“Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9).”
BackgroundReceptors for glucagon-like peptide-1(7–36) amide on rat insulinoma-derived cells
Göke, R., & Conlon, J. M. (1988) · Journal of Endocrinology · doi:10.1677/joe.0.1160357 · Cited by 147 · cited 1×
“Preceding that, the receptor was identified in numerous cell types and organs, most obviously the pancreatic -cell but also in rat lung and brain by studies using either ligand binding or functional assays (4, 5).”
BackgroundJositsch, G., Papadakis, T., Haberberger, R. V., Wolff, M., Wess, J., & Kummer, W. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0365-9 · Cited by 143
Reiner, T., Thurber, G., Gaglia, J., Vinegoni, C., Liew, C. W., Upadhyay, R., Kohler, R. H., Li, L., Kulkarni, R. N., Benoist, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109859108 · Cited by 120
Kanse, S. M., Kreymann, B., Ghatei, M. A., & Bloom, S. R. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)81063-9 · Cited by 104 · cited 1×
“Preceding that, the receptor was identified in numerous cell types and organs, most obviously the pancreatic -cell but also in rat lung and brain by studies using either ligand binding or functional assays (4, 5).”
BackgroundLack of specificity of antibodies directed against human beta-adrenergic receptors
Hamdani, N., & van der Velden, J. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0392-1 · Cited by 84
Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice
Lü, X., & Bartfai, T. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0394-z · Cited by 74
Duct System of the Rabbit Lacrimal Gland: Structural Characteristics and Role in Lacrimal Secretion
Ding, C., Parsa, L., Nandoskar, P., Zhao, P., Wu, K., & Wang, Y. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4687 · Cited by 72 · cited 11×
“Two GLP-1 analogs, liraglutide and exenatide, have been approved for clinical use and act as agonists of the GLP-1 receptor (GLP-1R), a member of the glucagon receptor family of G protein-coupled receptors (GPCRs) (1).”
MethodInfluentialShould we be cautious on the use of commercially available antibodies to dopamine receptors?
Bodei, S., Arrighi, N., Spano, P., & Sigala, S. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0384-6 · Cited by 62
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 42 · cited 1×
“Human GLP-1R-transfected cells typically express 100-fold higher levels of receptors than cells with endogenous expression of the receptor (27), and based on this, we find it unlikely that protocol optimization could lead to the generation of specific immunoreactivity signals in human paraffin-embedded samples using a…”
BackgroundSelf-citationDichmann, D. S., Rescan, C., Frandsen, U., & Serup, P. (2003) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540305100314 · Cited by 12 · cited 1×
“For all antibodies, a cytoplasmic staining of cells in human islets of Langerhans is presented by the suppliers to support the specificity of GLP-1R in IHC protocols; however, pancreas islets are known to frequently give rise to false-positive staining in IHC studies (24).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“The majority of antisera used to localize mouse and human GLP1R expression do not in fact recognize the GLP-1R under commonly utilized experimental conditions (Panjwani et al., 2013; Pyke and Knudsen, 2013).”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Self-citationThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Metadata
- Authors
- Pyke, C., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 154
- Issue
- 1
- Pages
- 4-8
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2050866589
- Cited by
- 154
- References
- 29
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 19 · 2019: 11 · 2018: 6 · 2017: 18 · 2016: 11 · 2015: 19 · 2014: 24 · 2013: 9
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, GLP-1 receptor agonists, liraglutide, exenatide, DPP-4 inhibitors, macrophages, hepatocytes, receptor localization, type 2 diabetes, atherosclerosis, hepatic steatosis, G protein-coupled receptors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.